Physician
West Michigan Cancer Center
West Michigan Cancer Center was paid $4.70M by Medicaid between Jan 2018 and Nov 2024, across 56 billing codes. Its largest line is J9271, Injection, pembrolizumab, 1 mg — 64% of everything it billed.
33Billing provider infoWEST MICHIGAN CANCER CENTER
KALAMAZOO, MI 49007
KALAMAZOO, MI 49007
33aNPI1447261730assigned 08/11/2006
33bProvider typeGynecologic Oncology Physician
28Total paid$4.70M
24GClaims46,668
24DCodes billed56
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Gynecologic Oncology Physician providers in Michigan
Rank by total paid#1 of 6
Median peer was paid$12K
This provider vs. median379×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,306 | $511K | |
| 2019 | 15,129 | $1.64M | |
| 2020 | 14,778 | $2.29M | |
| 2021 | 1,215 | $186K | |
| 2022 | 250 | $18K | |
| 2023 | 266 | $20K | |
| 2024incomplete | 724 | $33K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 64% | 374 | 282 | $3.03M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.6% | 6,236 | 5,150 | $358K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 4.7% | 3,180 | 1,843 | $222K |
| J2505 | Injection, pegfilgrastim, 6 mg | 4.4% | 47 | 36 | $206K |
| J1453 | Injection, fosaprepitant, 1 mg | 4.0% | 900 | 566 | $186K |
| J2469 | Injection, palonosetron hcl, 25 mcg | 3.2% | 1,783 | 1,083 | $148K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.0% | 2,526 | 2,282 | $93K |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.8% | 142 | 138 | $82K |
| 80053 | Comprehensive metabolic panel | 1.0% | 5,602 | 4,120 | $47K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,178 | 1,255 | $41K |
| 85027 | <1% | 7,619 | 5,001 | $40K | |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 398 | 363 | $32K |
44 more codes
| 99205 | Prolong outpt/office vis | <1% | 274 | $31K |
| 96417 | <1% | 772 | $30K | |
| 96367 | <1% | 1,129 | $23K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 166 | $14K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 329 | $12K |
| 96415 | <1% | 468 | $11K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,138 | $11K |
| 96411 | <1% | 284 | $10K | |
| 83735 | <1% | 1,769 | $9K | |
| 99245 | <1% | 66 | $8K | |
| 82728 | <1% | 669 | $7K | |
| 96523 | <1% | 483 | $7K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 278 | $7K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 69 | $6K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 81 | $5K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 319 | $4K |
| 83615 | <1% | 737 | $3K | |
| 96368 | <1% | 325 | $3K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 109 | $3K |
| 84466 | <1% | 280 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,130 | $2K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 191 | $2K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 124 | $1K |
| 83540 | <1% | 292 | $1K | |
| 90686 | <1% | 81 | $1K | |
| 99441 | <1% | 115 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,546 | $758.70 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 79 | $627.82 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 281 | $617.53 |
| 84439 | <1% | 95 | $595.61 | |
| 84100 | <1% | 139 | $524.28 | |
| 99442 | <1% | 38 | $509.04 | |
| 96402 | <1% | 17 | $317.34 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 399 | $273.05 |
| 86304 | <1% | 15 | $248.95 | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 26 | $238.12 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 250 | $214.32 |
| 82378 | <1% | 15 | $175.80 | |
| 82607 | <1% | 14 | $112.74 | |
| 81001 | <1% | 21 | $61.32 | |
| 85045 | <1% | 14 | $46.20 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 17 | $19.00 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 15 | $17.17 |
| S0028 | Injection, famotidine, 20 mg | <1% | 24 | $12.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMIRRO, JOSEPH (PRESIDENT/CEO/CMO)
Parent organizationWEST MICHIGAN CANCER CENTER
| Provider | Location | Paid |
|---|---|---|
| West Michigan Cancer Center | Kalamazoo, MI | $888K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.